ALS Clinical Trials

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that primarily attacks motor neurons in the brain and the spinal cord. The disease leads to the gradual deterioration and eventual death of motor neurons, which are crucial for controlling voluntary muscles.

Navigating the regulatory landscape is critical for the success of clinical trials in ALS. The US FDA sets stringent standards to ensure that new treatments are safe and effective. Understanding these regulatory requirements and implementing strategies to meet them are essential steps in the development and approval process of new ALS treatments. 


ALS is most commonly diagnosed between the ages of

40&70





ALS accounts for approximately

2%

of all neurogenerative disorders globally

 

ALS affects approximately

5

in 100,000 people worldwide annually

 

 

Our clinical team has over

120

years of combined clinical trial experience

 

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting an ALS clinical trial.

iNGENū CRO - ALS-1

In light of the significant impact ALS has on individuals and society as a whole, continued research and awareness efforts are crucial to improve diagnosis, treatment, and ultimately, the quality of life for those living with this disease.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new ALS treatments.